Tesofensine vs semaglutide: evidence, cost, and legality

Which is better, tesofensine or semaglutide?

Semaglutide wins on evidence (multiple phase 3 trials with weight and cardiovascular outcomes versus a single 24 week phase 2 trial), on safety direction (it lowers cardiovascular events, while tesofensine raised heart rate by about 7 beats per minute and blood pressure at the top dose), and on regulatory status (FDA approved versus never nominated for compounding and no US marketing authorization). Tesofensine's phase 2 weight loss was substantial, but without phase 3 data or a lawful US source it is not a comparable option. [1] [2] [3] [4] [5] [7]

How do tesofensine and semaglutide compare?

Tesofensine and Semaglutide compared by dimension
Dimension	Tesofensine	SemaglutideFavored
Drug type [1] [5]	Oral small molecule (not a peptide) that inhibits serotonin, noradrenaline, and dopamine reuptake.	31 amino acid GLP-1 receptor agonist peptide, acylated for once weekly dosing.
Evidence grade [1] [3] [4]	Human RCT, but one phase 2 trial in obesity (203 adults, 24 weeks); no published phase 3 program.	Human RCT, many phase 3 trials, including STEP 1 (1,961 adults, 68 weeks) and SELECT (17,604 adults).
Weight loss [1] [3]	6.7, 11.3, and 12.8 kg at 0.25, 0.5, and 1.0 mg daily versus 2.2 kg on placebo with diet at 24 weeks (placebo adjusted 4.5%, 9.2%, and 10.6%).	14.9% versus 2.4% with placebo at 68 weeks with 2.4 mg weekly.
Note: Cross-trial comparisons are unreliable because the trials differed in length, diet intensity, and population. No direct comparison exists.
Cardiovascular effects [1] [2] [4]	Heart rate rose about 7.4 beats per minute at 1.0 mg and blood pressure rose at that dose; long term cardiovascular safety not established.	20% relative reduction in major adverse cardiovascular events in SELECT (hazard ratio 0.80).
Common side effects [1] [3] [5]	Dry mouth, nausea, constipation, diarrhea, and insomnia; mood changes possible given its dopaminergic and serotonergic action.	Nausea (44% versus 16% placebo), diarrhea, vomiting, and constipation, highest during dose escalation; gallbladder disease and rare pancreatitis.
Key interactions [2] [5]	Theoretical serotonin syndrome and hypertensive risk with MAO inhibitors and serotonergic antidepressants; additive effects with stimulants.	Hypoglycemia with insulin or sulfonylureas; delayed gastric emptying can change absorption of oral drugs.
Regulatory status [5] [6] [7] [8]	Not FDA approved, no 503A nomination, and not on any compounding list; no lawful US source outside a trial.	FDA approved as Wegovy, Ozempic, and Rybelsus; shortage based compounding ended in 2025.
WADA status [9]	Unclear; not named, but could fall under S0 non-approved substances or S6 stimulants.	Not prohibited.
Route and frequency [1] [5]	Oral, once daily (trial doses 0.25 to 1.0 mg, with 0.5 mg the best balance).	Subcutaneous injection once weekly, titrated to 2.4 mg (Wegovy), or oral tablet once daily.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Tesofensine and Semaglutide: grade, status, and cost
Attribute	Tesofensine	Semaglutide
Class	Oral small molecule triple monoamine (serotonin, noradrenaline, dopamine) reuptake inhibitor; not a peptide	GLP-1 receptor agonist (31 amino acid analog of human GLP-1, acylated for once weekly dosing)
What it is	Not a peptide: an oral triple reuptake inhibitor that produced about 10% placebo adjusted weight loss over 24 weeks in a phase 2 RCT. Not FDA approved.	FDA approved GLP-1 agonist with about 15% average weight loss in a 68 week RCT and proven cardiovascular benefit.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: Unscheduled	Regulatory: FDA approved
Compounding	Not FDA approved and not on any FDA compounding list as of the pages current to April 2026. It is a synthetic small molecule with no US marketing authorization and no 503A nomination, so there is no lawful basis for a US compounding pharmacy to dispense it. Some products sold online as tesofensine are unverified imports or research chemicals.	FDA approved products (Ozempic 2017, Rybelsus 2019, Wegovy 2021). FDA removed semaglutide from the drug shortage list on February 21, 2025; compounding by 503A pharmacies had to stop by April 22, 2025 and by 503B outsourcing facilities by May 22, 2025, except for a documented patient specific clinical need. FDA has warned about unapproved compounded and counterfeit GLP-1 products and salt forms (semaglutide sodium, semaglutide acetate) that are not the approved active ingredient. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms.
WADA	WADA: WADA status unclear	WADA: Not WADA prohibited
Routes	Oral tablet or capsule, once daily	Subcutaneous injection once weekly (Ozempic, Wegovy), Oral tablet once daily (Wegovy tablets, Ozempic tablets, Rybelsus)
Typical cost	Not available through licensed US channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	Manufacturer list price is 1,349.02 USD per month for Wegovy and 1,027.51 USD for Ozempic (checked 2026-09-22), falling to 675 USD for both on January 1, 2027. Manufacturer self-pay prices run 149 to 499 USD per month by product and dose, with the Wegovy pen at 349 USD. With commercial insurance the manufacturer savings offer can bring a covered prescription to 25 USD per month, and eligible Medicare Part D enrollees pay 50 USD per month for Wegovy under the Medicare GLP-1 Bridge (July 2026 to December 2027). A 2024 study found compounded semaglutide at a median 231 USD for the first month during the shortage; compounding is now limited to patient specific needs.
Last verified	Sep 22, 2026	Sep 27, 2026

Has tesofensine been tested directly against semaglutide?

No published trial has compared tesofensine and semaglutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do tesofensine and semaglutide cost?

Typical cost of Tesofensine and Semaglutide
Dimension	Tesofensine	Semaglutide
Typical cost	Not available through licensed US channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	$149 to $1,349 per month
Price detail	Tesofensine price by channel	Semaglutide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is tesofensine as effective as semaglutide?

It has not been compared directly. Tesofensine produced about 9% to 11% placebo adjusted weight loss at 24 weeks in one phase 2 trial, while semaglutide produced 14.9% versus 2.4% on placebo at 68 weeks in phase 3. The trials differed too much to rank them precisely, and semaglutide's evidence base is far larger. [1] [3]

Is tesofensine a peptide?

No. Tesofensine is an oral small molecule that blocks the reuptake of serotonin, noradrenaline, and dopamine. It is often marketed alongside peptides but works through brain neurotransmitters rather than hormone receptors. [1]

Is tesofensine safe for the heart?

That has not been established. In the phase 2 trial the highest dose raised heart rate by about 7 beats per minute and increased blood pressure, and reviewers flagged cardiovascular safety as the key question for later trials. Semaglutide, by contrast, lowered major cardiovascular events in SELECT. [1] [2] [4]

Can I get tesofensine legally in the United States?

No. It has no FDA approval, no compounding nomination, and is not on any FDA compounding list, so there is no lawful US source outside a clinical trial. Semaglutide is available by prescription. [7] [8]

Is there a pill alternative to semaglutide injections?

Yes, semaglutide itself comes as a once daily oral tablet (Rybelsus for type 2 diabetes, and an oral Wegovy formulation), so choosing tesofensine for the pill form is not necessary. [5]

Conditions studied

From the blog

Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Tesofensine vs semaglutide: evidence, cost, and legality. https://peptideagent.ai/compare/tesofensine-vs-semaglutide
HTML link: <a href="https://peptideagent.ai/compare/tesofensine-vs-semaglutide">Tesofensine vs semaglutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Tesofensine vs semaglutide

The short answer